drugset / Trial / NCT02334787
A Phase 1 Trial of OPA-15406 Ointment in Healthy Adult Male Subjects
RandomizedParallel-groupDouble-blindTreatment
Summary
To assess the safety (especially skin findings) and pharmacokinetics by applying 0.3%, 1%, or 3% formulation of 5g OPA-15406 ointment to a 1000 cm2 area as a single-dose and as a multiple-dose twice daily for 2 weeks in Japanese healthy adult male subjects.
Timeline
- Start
- 2015-01
- Primary completion
- 2015-02
- Completion
- 2015-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Difamilast | Small molecule | 0.3 % | — |
| Subject | Difamilast | Small molecule | 1 % | — |
| Subject | Difamilast | Small molecule | 3 % | — |